TY - JOUR T1 - COVID-19 infection in Crohn’s disease under treatment with adalimumab JF - Gut JO - Gut SP - 1364 LP - 1365 DO - 10.1136/gutjnl-2020-321240 VL - 69 IS - 7 AU - Antonio Tursi AU - Gioacchino Angarano AU - Laura Monno AU - Annalisa Saracino AU - Fabio Signorile AU - Aurelia Ricciardi AU - Alfredo Papa Y1 - 2020/07/01 UR - http://gut.bmj.com/content/69/7/1364.abstract N2 - Jin et al described recently 74 cases of people having COVID-19 and experiencing gastrointestinal symptoms.1 In Italy, we are managing a dramatically increasing number of people infected with severe acute respiratory syndrome corona virus 2, the virus causing COVID-19.2 3 Despite the Italian Government has implemented extraordinary measures to restrict viral spread, including significant decrease of air and train traffic within the country, cases are increasing (>75 000 people until 26 March 2020) also in other regions than Lombardy, which is the main Italian region affected from COVID-19 (>35 000 people until 26 March 2020).4 This means that a lot of people under immunosuppressive-immunomodulating therapies could be infected by this virus, and that the immunosuppressive status could influence both the status of the basic disease and both the course of pulmonary disease.A 30-year-old male was admitted on emergency department of the Bari University Hospital, Puglia Region, Southern Italy, on 12 March 2020 (with a low number of cases until that date) due to sudden occurrence … ER -